We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
COVID-19 Vaccine Race Heats Up: Drugmarkers on Final Lap
Read MoreHide Full Article
Drugmakers have finally started releasing results of final-stage trials of their experimental coronavirus vaccine candidates. On Nov 30, Moderna, Inc. (MRNA - Free Report) once again raised hopes among millions after it said that its coronavirus vaccine is 94% safe.
After 13.4 million COVID-19 cases, a vaccine now looks possible with multiple drugmakers gearing up to apply for emergency use approval of their candidates from the FDA. Earlier this month, Pfizer, Inc. (PFE - Free Report) and BioNTech SE (BNTX - Free Report) had said that their vaccine candidate has proven effective in preventing coronavirus and have also applied to the FDA for emergency use authorization.
Moderna Moves a Step Ahead
Moderna applied for emergency use authorization of its coronavirus vaccine after it said that that it had 94% efficacy and is safe. If the FDA gives the emergency use authorization, several Americans could get the two-dose vaccine within weeks. The company reportedly is planning to roll out 20 million doses of vaccine by the end of the year.
According to a CNBC report, Moderna, after evaluating 196 cases from the final-stage trial on 30,000 volunteers, observed 185 cases of coronavirus in the placebo group against 11 cases observed in the group that got the vaccine doses. Monday’s results were more concrete than the announcement made in early November when Moderna had said the vaccine was 94% effective based on the results of 95 COVID-19 patients.
Following the announcement, Moderna’s shared surged 20.2%. Shares of other drugmakers also jumped. Pfizer’s shares gained 2.9%, while BioNTech gained 13%. Moderna and Pfizer each carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Who Will Win the Vaccine Race?
The vaccine race has heated up once again with final-stage trial results of candidates coming up and applications being filed with the FDA for emergency use authorization.
On Nov 9, FDA gave approval to Eli Lilly and Company (LLY - Free Report) for the emergency use of its monoclonal antibody drug bamlanivimab to treat COVID-19 patients. In mid-November, Pfizer and BioNTech had announced that their jointly developed vaccine was 95% effective. The duo applied for emergency use authorization last week.
The University of Oxford and AstraZeneca plc’s (AZN - Free Report) COVID-19 vaccine proved to produce immune responses in both adults and young people, with an efficacy of 74% in the final-stage trials.
Going back to May, Gilead Sciences, Inc. (GILD - Free Report) had received an emergency-use authorization for its experimental coronavirus drug from the FDA based on preliminary results from two clinical trials: one conducted by the NIAID and the other by Gilead.
Although coronavirus cases are on the rise and fears are mounting, drugmakers have once again started showing hope with positive results on the vaccine front. It now needs to be seen who sprints to the finish line first.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Image: Bigstock
COVID-19 Vaccine Race Heats Up: Drugmarkers on Final Lap
Drugmakers have finally started releasing results of final-stage trials of their experimental coronavirus vaccine candidates. On Nov 30, Moderna, Inc. (MRNA - Free Report) once again raised hopes among millions after it said that its coronavirus vaccine is 94% safe.
After 13.4 million COVID-19 cases, a vaccine now looks possible with multiple drugmakers gearing up to apply for emergency use approval of their candidates from the FDA. Earlier this month, Pfizer, Inc. (PFE - Free Report) and BioNTech SE (BNTX - Free Report) had said that their vaccine candidate has proven effective in preventing coronavirus and have also applied to the FDA for emergency use authorization.
Moderna Moves a Step Ahead
Moderna applied for emergency use authorization of its coronavirus vaccine after it said that that it had 94% efficacy and is safe. If the FDA gives the emergency use authorization, several Americans could get the two-dose vaccine within weeks. The company reportedly is planning to roll out 20 million doses of vaccine by the end of the year.
According to a CNBC report, Moderna, after evaluating 196 cases from the final-stage trial on 30,000 volunteers, observed 185 cases of coronavirus in the placebo group against 11 cases observed in the group that got the vaccine doses. Monday’s results were more concrete than the announcement made in early November when Moderna had said the vaccine was 94% effective based on the results of 95 COVID-19 patients.
Following the announcement, Moderna’s shared surged 20.2%. Shares of other drugmakers also jumped. Pfizer’s shares gained 2.9%, while BioNTech gained 13%. Moderna and Pfizer each carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Who Will Win the Vaccine Race?
The vaccine race has heated up once again with final-stage trial results of candidates coming up and applications being filed with the FDA for emergency use authorization.
On Nov 9, FDA gave approval to Eli Lilly and Company (LLY - Free Report) for the emergency use of its monoclonal antibody drug bamlanivimab to treat COVID-19 patients. In mid-November, Pfizer and BioNTech had announced that their jointly developed vaccine was 95% effective. The duo applied for emergency use authorization last week.
The University of Oxford and AstraZeneca plc’s (AZN - Free Report) COVID-19 vaccine proved to produce immune responses in both adults and young people, with an efficacy of 74% in the final-stage trials.
Going back to May, Gilead Sciences, Inc. (GILD - Free Report) had received an emergency-use authorization for its experimental coronavirus drug from the FDA based on preliminary results from two clinical trials: one conducted by the NIAID and the other by Gilead.
Although coronavirus cases are on the rise and fears are mounting, drugmakers have once again started showing hope with positive results on the vaccine front. It now needs to be seen who sprints to the finish line first.
Legal Marijuana: An Investor’s Dream
Imagine getting in early on a young industry primed to skyrocket from $17.7 billion in 2019 to an expected $73.6 billion by 2027.
Although marijuana stocks did better as the pandemic took hold than the market as a whole, they’ve been pushed down. This is exactly the right time to get in on selected strong companies at a fraction of their value before COVID struck. Zacks’ Special Report, Marijuana Moneymakers, reveals 10 exciting tickers for urgent consideration.
Download Marijuana Moneymakers FREE >>